Eu IVDR Compliance Authorized Representative Service In Spain

Scope and evidence must be confirmed before any paid tests or filings.

For an IVD legal manufacturer subject to IVDR Article 11, an accepted authorised-representative mandate is a market-placement requirement; EU/EEA and EU–Türkiye arrangements must be checked before deciding it applies. A representative established in Spain can cover the EU, but Spain is not a compulsory location when products are sold there. Appointing an AR is not a CE certificate, an importer appointment or a Spanish commercialisation notification.

Decide whether a Spanish IVDR representative is the right appointment

Confirm the legal manufacturer’s place of establishment, IVDR status and the device group before signing. The table separates the EU requirement from the commercial choice of Spain.

This general rule is subject to EEA arrangements and a specific EU–Türkiye customs-union interpretation: establishment outside the EU does not by itself settle every case.

Situation	AR decision	Practical consequence
Legal manufacturer is established outside the EU/EEA and outside Türkiye and plans to place an IVDR device on the EU market	An EU-established AR is required by IVDR Article 11.	Spain is an available base, not the only permissible Member State.
Legal manufacturer is established in an EU Member State	No Article 11 non-EU-manufacturer AR appointment is required.	Assess manufacturer, importer/distributor and Spanish notification duties separately.
Legal manufacturer is established in Norway, Iceland or Liechtenstein (EEA)	Do not treat the company as an ordinary third-country manufacturer for this appointment decision: EEA arrangements extend the relevant EU medical-device framework.	Confirm the precise EEA establishment and actor data before deciding that a Spanish AR must be appointed.
Manufacturer established in Türkiye, or a non-EU/EEA manufacturer using an AR established in Türkiye	Do not assume that a separate EU/Spain-based AR is mandatory: the Commission’s EU–Türkiye medical-device customs-union notice recognises Turkish manufacturers and, for third-country manufacturers, a single AR in either Türkiye or the EU.	Verify establishment, device scope and the recognised mandate under the specific customs-union arrangements; continue to assess Spain’s RECOPS and supply-chain obligations.
Non-EU manufacturer already has an AR established in another EU Member State for the same generic device group	Do not appoint a second concurrent AR for that group.	Check the existing mandate and its covered device groups; Spanish sales alone do not demand a Spanish AR.
Product is not an IVD within IVDR scope	This IVDR route cannot be assumed.	Check MDR or other applicable law before appointing anyone.
Product is for a performance study only, or claimed to be a legacy IVDD device	The market-placement and transition analysis is fact-specific.	Check intended use, Article 110 conditions and actual market activity before giving a categorical answer.

Define the mandate and the limits of representation

Under IVDR Article 11, the written mandate must be accepted by the AR and cover at least all devices in the same generic device group. The manufacturer keeps non-delegable IVDR duties; an AR does not become the manufacturer. An AR has specific verification, access, communication and cooperation duties, and may incur joint and several liability under the conditions of Article 11(5).

Function	Responsible party / AR boundary
Technical documentation, performance evaluation, risk management, QMS and conformity assessment	Manufacturer; the AR verifies specified documents and conformity-route evidence, not authorship or product approval.
Written mandate, document availability, authority requests, complaints and corrective-action cooperation	Manufacturer enables the AR; AR performs its Article 11 tasks and must have access to relevant records.
EUDAMED actor registration, device links and SRN checks	Manufacturer and AR each meet their own relevant registration duties; confirm exact actor/device records.
Spanish commercialisation notice and Spanish-language user information	The economic operator actually commercialising in Spain must assess RECOPS; an AR can file under a documented manufacturer delegation where AEMPS allows it.

Separate EUDAMED registration from Spain’s RECOPS notification

EUDAMED actor/device registration is an EU layer; RECOPS is a separate Spanish market-commercialisation layer. The first four EUDAMED modules became mandatory on 28 May 2026, subject to transitional provisions. Spain opened RECOPS on 15 June 2026 under Royal Decree 942/2025. A Spanish AR’s EUDAMED SRN does not itself complete any RECOPS communication. The four modules do not impose the same action on every business: manufacturers submit device data, the AR registers as an actor, notified bodies manage certificates and the market-surveillance module is principally for authorities.

For IVDs sold in Spain, RECOPS covers all IVDR risk classes; each economic operator commercialising in Spain considers its own notice, subject to the AEMPS guidance on group entities, delegation and retail exemptions.
Before submitting in RECOPS, the device generally needs to be registered and visible in EUDAMED; AEMPS describes a limited handling situation when visibility is not yet possible. Do not mistake that for a general exemption.
A RECOPS communication identifies the operator and device/UDI-DI, actual Spanish marketing start date, labels and instructions for use. Keep changes, cessation and annual confirmations under control.
At putting into service in Spain, information required by IVDR Annex I, section 20 must be available at least in Castilian Spanish (Royal Decree 942/2025, Article 5(2)). The Spanish-language requirement is not a universal requirement to translate the whole technical file.
AEMPS is the national competent authority. If the Spanish entity also physically imports devices from a third country, examine the separate AEMPS operating-licence requirement; AR status alone does not settle import authorisation.
If the Spain-established AR also distributes or sells IVDs in Spain, check the separate prior activity notice to the competent autonomous-community health authority for its registered office and, where different, its warehouses (Royal Decree 942/2025, Article 19(3)); an AR mandate alone does not satisfy that distributor rule.
If an IVD is visible in EUDAMED but is still absent from RECOPS after more than 48 hours, raise an AEMPS ServiceDesk case with the missing UDI-DI rather than treating the EUDAMED listing as a RECOPS filing.

Apply the 2026 RECOPS timing test to each device

The date of EUDAMED device notification—not the date of the AR contract—determines which AEMPS transition rule to check. The following is a filing decision aid, not an extension of any IVDR conformity deadline.

Device / Spanish activity	RECOPS timing and action
Device notified in EUDAMED before 28 May 2026	AEMPS states a maximum of six months from 28 May 2026 to communicate it in RECOPS under the transition. Check the record, the responsible Spanish commercialising operator and that the product is visible.
Device notified in EUDAMED on or after 28 May 2026; new Spanish commercialisation	Communicate it in RECOPS before the start of marketing in Spain, once notified and visible in EUDAMED. The actual marketing start date must be reported.
Device not yet notified or visible in EUDAMED	RECOPS cannot accept the communication. AEMPS allows continued marketing for products that cannot be communicated solely because of that absence, with the RECOPS filing due once visible; this is not an exemption from EU conformity or other market-entry obligations.
Device previously communicated in CCPS or RPS	Old communications are not migrated automatically. File a new RECOPS notice; where the earlier notice belongs to the same company, cite its number to assess exemption from the initial RECOPS fee.

If Spanish commercialisation began before RECOPS opened on 15 June 2026, AEMPS says to notify as soon as possible once the product is visible and report the genuine historic start date. AEMPS FAQs (updated 2 October 2026) explain these distinct cases; do not treat a distributor’s registration as a blanket exemption for unrelated operators.

Build the appointment and product evidence pack

Prepare the following before a candidate confirms acceptance. This is a contractual onboarding checklist, not a claim that all items are separately filed with the AEMPS.

Legal manufacturer identity and established address; proof of which company is the legal manufacturer.
Catalogue with intended purpose, IVD rationale, IVDR risk class, generic device groups, model/UDI-DI and target EU markets.
Current EU declaration of conformity; applicable notified-body certificate and its scope, if relevant; legacy-transition evidence if claimed.
Technical-documentation access arrangements, version index, performance evidence and quality-system contact; no blanket transfer of manufacturer duties.
Existing or proposed AR/PRRC details, draft written mandate and procedures for document provision to authorities.
EU importer/distributor chain, who first commercialises in Spain and the signed RECOPS delegation (if used).
Proposed labels/IFU including AR identity, Spanish language review, complaint/vigilance contact route and escalation contacts.

Run a controlled appointment and handover workflow

An effective AR service is an ongoing control process, not a certificate sale. Allocate each step in writing and preserve audit evidence.

Map product groups and confirm the legal manufacturer and whether IVDR Article 11 applies.
Due-diligence the Spain-established AR: legal presence, IVDR competence, PRRC access, continuity, document-security and escalation capability.
Execute the accepted written mandate; verify the AR identity on relevant product information and the manufacturer’s regulatory records.
Reconcile EUDAMED actor/SRN and device data; separately determine the operator and submission path for RECOPS, Spanish IFU and any import licence.
Run periodic complaint, serious-incident, corrective-action and authority-request drills; keep version changes and replacement/exit arrangements documented.

Handle legacy devices, changes and warning signs

Before launch or any change, revisit the facts rather than relying on a generic “IVDR approved” statement.

Changing AR: Article 12 calls for documented dates, inventory/document transfer, label transition and post-termination complaint forwarding; never create an uncovered interval.
An IVDD-era device is not automatically grandfathered: test the IVDR Article 110 transitional conditions and current certificate/device facts; special dates cannot be determined without those facts.
A changed intended purpose, device group, certification status, importer or Spanish seller can change the mandate or RECOPS responsibility.
Warning signs: “AR certificate guarantees CE”, refusal to sign a precise mandate, missing document access, two ARs for one generic group or confusion between EUDAMED and RECOPS.
A manufacturer’s IVDR non-compliance can trigger the AR duty to terminate its mandate and immediately inform its Member State authority and, where applicable, the notified body (Articles 11(3)(h) and 11(6)); the contract must have a documented escalation/exit route.

Next decision: request a scope-based mandate

Send a device-family inventory, manufacturer and importer details, intended Spanish sales model, current CE/IVDR evidence and existing AR agreement (if any) to the proposed Spain-established AR. Request written confirmation of acceptance, the generic-group scope, EUDAMED responsibilities, Spanish RECOPS responsibility, response arrangements and exclusions. Do not place an unqualified device on the market merely because an AR contract is signed.

For wider matters outside this appointment task, see the EU-wide IVDR representative framework, CE-marking implementation in Spain, the MDR route for devices that are not IVDs.

Questions specific to appointing an IVDR AR in Spain

Must my EU representative be in Spain if I sell IVD tests there?

Under Article 11, manufacturers normally need an accepted representative for EU placement where that obligation applies. However, EEA and EU–Türkiye customs-union arrangements can change whether an additional EU representative is required. A representative based in another qualifying location may suffice; Spain is not automatically necessary. Check RECOPS separately.

Can an authorised representative submit the Spanish RECOPS communication for our non-EU manufacturer?

Potentially, but not automatically: AEMPS recognises manufacturer delegation to an AR where the signed agreement documents that task. Confirm who commercialises the product and the applicable AEMPS examples.

Does a Spanish AR obtain the IVDR CE certificate for a class C test?

No. Conformity assessment and any required notified-body certificate belong to the manufacturer’s IVDR route. The AR verifies relevant records and fulfils the mandate; appointment alone does not clear class C market entry.

Does the AR’s EUDAMED registration replace the Spanish notification?

No. EUDAMED actor/device registration and AEMPS RECOPS communication are separate. RECOPS generally imports visible device information from EUDAMED.

What if we are replacing our existing EU representative?

Plan an Article 12 transfer agreement with outgoing/incoming responsibilities, dates, records, labeling and future complaints. Validate generic-group coverage and update affected registration and supply-chain records.